Relevant bibliographies by topics / Cancer du sein basal-Like

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Cancer du sein basal-Like'

Author: Grafiati
Published: 30 November 2024
Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Cancer du sein basal-Like.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Cancer du sein basal-Like"

1

Treilleux, Isabelle, and Blandine Morellon-Mialhe. "Le cancer du sein de phénotype basal." Annales de Pathologie 29, no. 3 (2009): 180–86. http://dx.doi.org/10.1016/j.annpat.2009.04.001.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Garcia de la Fuente, I., F. Jolicoeur, A. Robidoux, I. Gorska, D. Balicki, and L. Gaboury. "Caractérisation du cancer du sein de phénotype basal." Annales de Pathologie 26, no. 1 (2006): 69–70. http://dx.doi.org/10.1016/s0242-6498(06)70671-x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Vincent-Salomon, A., G. Macgrogan, E. Charaffe-Jauffret, J. Jacquemier, and L. Arnould. "Identification en pratique clinique des carcinomes basal-like du sein : des carcinomes « triple zéro/BRCA1-like »." Bulletin du Cancer 97, no. 3 (2010): 357–63. http://dx.doi.org/10.1684/bdc.2010.1062.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Leidy, Jennifer, Ashraf Khan, and Dina Kandil. "Basal-Like Breast Cancer: Update on Clinicopathologic, Immunohistochemical, and Molecular Features." Archives of Pathology & Laboratory Medicine 138, no. 1 (2014): 37–43. http://dx.doi.org/10.5858/arpa.2012-0439-ra.

Full text
Abstract:
Context.—Basal-like breast carcinoma (BLBC) is a distinct molecular subtype of breast carcinoma identified through gene expression profiling studies. Objective.—To provide the clinical background, the histologic profile, and the immunohistochemical profile of these tumors and discuss the current knowledge of their molecular signature and their implications on targeted molecular therapy. Data Sources.—Data were obtained from review of the pertinent peer-reviewed literature. Conclusions.—Basal-like breast carcinomas are aggressive tumors with poor prognosis. Lack of targeted therapy makes their
APA, Harvard, Vancouver, ISO, and other styles
5

Liu, Ming, Julia Y. S. Tsang, Michelle Lee, et al. "CD147 expression is associated with poor overall survival in chemotherapy treated triple-negative breast cancer." Journal of Clinical Pathology 71, no. 11 (2018): 1007–14. http://dx.doi.org/10.1136/jclinpath-2018-205342.

Full text
Abstract:
AimsIn breast cancer models, the functional roles of CD147 in proliferation, invasion and treatment resistance have been widely reported. However, there are only a few studies examining the clinicopathological correlation and prognostic relevance of CD147 in breast cancer, especially in relation to breast cancer molecular subtypes.MethodsIn this study, we analysed CD147 expression in a large cohort of breast cancers, correlating with clinicopathological features and the expression of a comprehensive panel of biomarkers in triple-negative breast cancer (TNBC) and non-TNBC subsets. Its relations
APA, Harvard, Vancouver, ISO, and other styles
6

Kardos, Jordan, Jonathan J. Melquist, David D. Chism, et al. "Evaluation of basal and luminal subtypes of urothelial carcinoma in African American and non-African American patients." Journal of Clinical Oncology 33, no. 7_suppl (2015): 305. http://dx.doi.org/10.1200/jco.2015.33.7_suppl.305.

Full text
Abstract:
305 Background: African American (AA) patients with urothelial carcinoma (UC) have been known to have a worse prognosis even when corrected for variables such as tumor stage and grade. Analysis of gene expression of several malignancies has resulted in the discovery of molecular subtypes with well-defined intrinsic biology. Recent studies in high grade (HG), muscle-invasive UC have led to the identification of two intrinsic, molecular subsets termed “luminal” and “basal” with characteristics of stages of urothelial differentiation, and that remarkably reflect the luminal and basal-like molecul
APA, Harvard, Vancouver, ISO, and other styles
7

Mayer, Ingrid A., Rebecca Dent, Tira Tan, Peter Savas, and Sherene Loi. "Novel Targeted Agents and Immunotherapy in Breast Cancer." American Society of Clinical Oncology Educational Book, no. 37 (May 2017): 65–75. http://dx.doi.org/10.1200/edbk_175631.

Full text
Abstract:
The treatment of breast cancer is generally determined according to breast cancer subtype: hormone receptor–positive (luminal), triple-negative (basal-like), and HER2-overexpressing breast cancer. Recent years have seen the development of exciting novel and potent therapeutics based on molecular pathways, immune modulation, and antibody conjugates. In this article, we cover new and emerging therapeutic areas and ongoing clinical trials that may result in further improvements in breast cancer outcomes.
APA, Harvard, Vancouver, ISO, and other styles
8

Chukwuma, Uzoigwe J., Nzegwu M. Arinze, Onyishi N. Thaddeus, et al. "The Histological Subtypes of Breast Cancer Seen in a Tertiary Hospital in South-East, Nigeria." Global Journal of Health Science 12, no. 6 (2020): 93. http://dx.doi.org/10.5539/gjhs.v12n6p93.

Full text
Abstract:
INTRODUCTION: Breast cancer is a disease with heterogeneous nature that may have different prognosis and respond to therapy differently despite similarities in histological type, grade and stage. It is common among women in both developed and developing countries of the world. 
 
 MATERIALS AND METHODS: This study was a 2-year retrospective study involving a systematic analysis of all the formalin-fixed paraffin-embedded tissue blocks previously diagnosed as breast cancers. The study occurred at the Department of Morbid Anatomy, University of Nigeria Teaching Hospital, Enugu
APA, Harvard, Vancouver, ISO, and other styles
9

Gao, Yang, Elena B. Kabotyanski, Jonathan H. Shepherd, et al. "Tumor Suppressor PLK2 May Serve as a Biomarker in Triple-Negative Breast Cancer for Improved Response to PLK1 Therapeutics." Cancer Research Communications 1, no. 3 (2021): 178–93. http://dx.doi.org/10.1158/2767-9764.crc-21-0106.

Full text
Abstract:
Polo-like kinase (PLK) family members play important roles in cell-cycle regulation. The founding member PLK1 is oncogenic and preclinically validated as a cancer therapeutic target. Paradoxically, frequent loss of chromosome 5q11–35, which includes PLK2, is observed in basal-like breast cancer. In this study, we found that PLK2 was tumor suppressive in breast cancer, preferentially in basal-like and triple-negative breast cancer (TNBC) subtypes. Knockdown of PLK1 rescued phenotypes induced by PLK2 loss both in vitro and in vivo. We also demonstrated that PLK2 directly interacted with PLK1 at
APA, Harvard, Vancouver, ISO, and other styles
10

Ladewig, Erik, Abbas Nazir, Christina Leslie, and Charles Sawyers. "Abstract 2048: Mutations in FOXA1 alter chromatin remodeling and cell fate in prostate organoids." Cancer Research 83, no. 7_Supplement (2023): 2048. http://dx.doi.org/10.1158/1538-7445.am2023-2048.

Full text
Abstract:
Abstract Genomic analysis of targeted patient tumor sequencing identified frequent mutations, 41% in prostate cancer (Li, et al., 2020) in the gene FOXA1, a developmentally important pioneer transcription factor (TF) in mammary and prostate tissues. Previous work by our group and others has shown that these FOXA1 mutations alter global chromatin accessibility and promote growth in prostate cells (Adams, 2019), but the underlying molecular details, including the identity of partner TFs, remain unclear. To address this topic, we generated mouse prostate organoids expressing Foxa1 alleles harbori
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Cancer du sein basal-Like"

1

Aho, Simon. "Rôle de la voie BMP dans l'émergence des cellules souches cancéreuses mammaires et l'initiation du cancer du sein basal-like." Electronic Thesis or Diss., Lyon 1, 2024. https://theses.hal.science/tel-04811400.

Full text
Abstract:
Introduction : Le cancer du sein est la première cause de décès par cancer chez la femme dans le monde. Il s’agit d’une maladie hétérogène dont il existe plusieurs sous-types moléculaires corrélés au pronostic. Parmi ces différentes entités, le sous-type basal-like présente le pronostic le plus défavorable. Il est caractérisé par une expression accrue de marqueurs de différentiation basale et une instabilité génétique importante, fréquemment due à des altérations de la recombinaison homologue. Il est également enrichi en cellules souches cancéreuses. Ces cellules semblent être impliquées dans
APA, Harvard, Vancouver, ISO, and other styles
2

Yakhni, Mohamad. "Inhibition de la synthèse des protéines, un traitement adapté aux cancers du sein triple négatifs des sous-types moléculaires autres que basal-like 1." Thesis, Université Clermont Auvergne‎ (2017-2020), 2018. http://www.theses.fr/2018CLFAS025.

Full text
Abstract:
Les cancers du sein triple négatifs (CSTN), sans mutations dans les gènes BRCA1 ou BRCA2 ou sans BRCAness sont, aujourd’hui, les tumeurs malignes du sein les plus difficiles à traiter. L’amélioration de leur traitement, pour toutes les phases de la maladie, est un important besoin médical non satisfait. Nous avons analysé l’effet de l’homoharringtonine, un inhibiteur naturel de la synthèse des protéines, approuvé pour le traitement de la leucémie myéloïde chronique, sur quatre lignées cellulaires représentant des CSTN, appartenant aux catégories génomiques agressives, mais sans mutation de BRC
APA, Harvard, Vancouver, ISO, and other styles
3

Dufour, Robin. "Différentes approches de l'optimisation du traitement du cancer du sein de phénotype "basal like" triple négatif par un anti-PARP : contournement des protéines "Multidrug Resistance" et traitement combiné radiothérapie / chimiothérapie. Spécialité." Thesis, Clermont-Ferrand 1, 2016. http://www.theses.fr/2016CLF1MM05/document.

Full text
Abstract:
Le cancer du sein de phénotype « Basal-like » triple négatif (BLTN) est particulièrement agressif et de mauvais pronostic. Il est insensible aux traitements hormonaux laissant pour seule stratégie de traitement la chimiothérapie conventionnelle. De ce fait, de nouvelles thérapeutiques ciblées sont en développement, tels que les inhibiteurs de la Poly-ADP-Ribose-Polymerase (PARP). Dans ce contexte, nos travaux de recherche ont été orientés sur l’optimisation du traitement des cancers du sein BLTN en modélisant l’action d’un anti-PARP modèle, l’Olaparib sur la lignée SUM1315 de phénotype BLTN. D
APA, Harvard, Vancouver, ISO, and other styles
4

Hassanein, Mohamed. "Facteurs prédictifs de mutation germinale BRCA1 dans le cancer du sein héréditaire." Thesis, Aix-Marseille 2, 2010. http://www.theses.fr/2010AIX20714.

Full text
Abstract:
En France, le cancer de sein héréditaire représente environ 2500 nouveaux cas par an, dont prés de la moitié est attribuée à la mutation du gène BRCA1.La recherche de la mutation par biologie moléculaire est un travail fastidieux, coûteux et long (8 mois d’attente environ actuellement).Pour trouver une solution à ce délai, nous avons étudié en immunohistochimie une série initiale de 21 anticorps répartis en 5 groupes : anticorps antiBrca1 du commerce, liés à la perte de l’inactivation de l’X, liés à la signature basale ou myoépithéliale, anticorps dits classiques du cancer de sein et finalemen
APA, Harvard, Vancouver, ISO, and other styles
5

LEVY, RAFAEL. "Oncogenes, facteurs de croissance et cancers du sein : revue de la litterature, etude de la regulation du recepteur a l'igf 1 dans la lignee mcf-7 et des polymorphismes des proto-oncogenes c-ha-ras 1 et c-mos dans des cas familiaux." Lille 2, 1989. http://www.theses.fr/1989LIL2M316.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Jehanno, Charly. "Régulation de l'activité de récepteur alpha des oestrogènes (ERα) par l'hypoxie et le facteur MKL1 dans un modèle de cellules cancéreuses mammaires". Thesis, Rennes 1, 2017. http://www.theses.fr/2017REN1B050/document.

Full text
Abstract:
Les œstrogènes, et en particulier l’œstradiol E2, régulent un nombre considérable de fonctions physiologiques au sein de l’organisme et permettent notamment l’établissement et le maintien des fonctions reproductives chez tous les vertébrés. L’E2 agit localement dans de multiples organes cibles via l’intermédiaire de ses récepteurs : ERα et ERβ. Par son action proliférative contribuant au renouvellement de l’épithélium mammaire, l’E2 ainsi que son récepteur ERα ont été associés au développement pathologique de tumeurs mammaires. Celles-ci sont qualifiées d’hormono-dépendantes car elles réponden
APA, Harvard, Vancouver, ISO, and other styles
7

Confort, Carole. "Etude d'une forme soluble du récepteur IGFII/M6P dans les cancers du sein." Montpellier 1, 1995. http://www.theses.fr/1995MON1T025.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Coutant, Pierre. "Valeur pronostique du dosage plasmatique de l'igf 1 dans le cancer du sein metastatique : etude portant sur 81 dossiers de patientes suivies au centre oscar lambret de lille." Lille 2, 1992. http://www.theses.fr/1992LIL2M238.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Bouchard, Alexanne. "La protéine de stress du réticulum endoplasmique GRP94 dans le cancer du sein triple négatif, intérêt diagnostique et thérapeutique." Electronic Thesis or Diss., Bourgogne Franche-Comté, 2023. https://nuxeo.u-bourgogne.fr/nuxeo/site/esupversions/8b1b931d-83a7-49fd-9779-012ad3949e79.

Full text
Abstract:
Le cancer du sein triple négatif (CSTN) est caractérisé par l’absence sur les cellules tumorales de récepteurs aux œstrogènes, à la progestérone ainsi que de HER2. Il s’agit du sous-type de cancer du sein le plus agressif et il est associé à un risque plus élevé de métastases. Il représente 15 à 20% de tous les cancers du sein. En raison du manque de cibles spécifiques, l'hormonothérapie et les médicaments ciblant HER2 sont inefficaces. Les CSTN représentent en fait un sous-groupe de tumeurs hétérogènes pouvant être classées en fonction de leurs caractéristiques moléculaires. Une meilleure com
APA, Harvard, Vancouver, ISO, and other styles
10

Houhou, Mona. "Caractérisation de sous-populations enrichies en cellules souches cancéreuses et rôle des régulateurs de la transition épithélio-mésenchymateuse dans la plasticité tumorale dans le cancer du sein de type basal." Thesis, Montpellier, 2017. http://www.theses.fr/2017MONTT043.

Full text
Abstract:
Il est généralement admis que le cancer du sein représente un ensemble de plusieurs maladies, définies comme des sous-types ayant des caractéristiques moléculaires et cliniques qui leurs sont propres. Une meilleure compréhension des mécanismes qui sous-tendent l'hétérogénéité du cancer du sein est essentielle au développement de thérapies mieux ajustées. Le concept de cellules souches cancéreuses (CSC) pourrait être un des clés de cette compréhension. A ce jour, un certain nombre de marqueurs ont été proposés pour isoler et caractériser les cellules souches dans le cancer du sein, mais aucun n
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Cancer du sein basal-Like"

1

Pires, Maira Moura. Basal-like breast cancer: Modeling its initiation and characterizing novel EGFR variants. [publisher not identified], 2012.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Green, Adèle C., Catherine M. Olsen, and David J. Hunter. Skin Cancer. Oxford University Press, 2018. http://dx.doi.org/10.1093/oso/9780190676827.003.0015.

Full text
Abstract:
Skin cancer is one of the few types of cancer for which exposure to the major carcinogen, solar ultraviolet (UV) radiation, is strongly implicated on the basis of descriptive epidemiologic data alone. There are three major forms of skin cancer considered in this chapter—melanoma, basal cell carcinoma (BCC), and squamous cell carcinoma (SCC)—and each appears to have different causal relations to the pattern and total amount of sun exposure. High-intensity UV exposure and long-term UV exposure appear to be involved differentially in the various skin cancers and their subtypes. Underlying molecul
APA, Harvard, Vancouver, ISO, and other styles
3

Skin Cancer. Exon Publications, 2024. https://doi.org/10.36255/skin-cancer.

Full text
Abstract:
Skin cancer is the most common type of cancer, caused by abnormal cell growth in the skin due to factors like ultraviolet (UV) radiation, genetic predisposition, and environmental exposures. Skin Cancer: Education for Patients and the Public serves as a comprehensive guide to understanding skin cancer, offering clear and practical information for patients, caregivers, and the general public. It begins with an explanation of what skin cancer is, followed by its types, including basal cell carcinoma, squamous cell carcinoma, and melanoma, each with distinct characteristics and treatment approach
APA, Harvard, Vancouver, ISO, and other styles
4

Grant, Warren, and Martin Scott-Brown. Principles of oncogenesis. Edited by Patrick Davey and David Sprigings. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780199568741.003.0322.

Full text
Abstract:
It is obvious that the process of developing cancer—oncogenesis—is a multistep process. We know that smoking, obesity, and a family history are strong independent predictors of developing malignancy; yet, in clinics, we often see that some heavy smokers live into their nineties and that some people with close relatives affected by cancer spend many years worrying about a disease that, in the end, they never contract. For many centuries scientists have struggled to understand the process that make cancer cells different from normal cells. There were those in ancient times who believed that tumo
APA, Harvard, Vancouver, ISO, and other styles
5

Ehrlich, Benjamin. Cajal’s Legacy. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780190619619.003.0001.

Full text
Abstract:
This chapter looks into the legacy of Santiago Ramón y Cajal. Historians rank Cajal alongside more recognizable names such as Darwin and Pasteur among the greatest biologists of the nineteenth century and Copernicus, Galileo, and Isaac Newton among the greatest scientists of all time. In his final testament to the neuron theory, Neuron Theory or Reticular Theory? Cajal reported to have seen more than a million neurons. Cajal’s drawings of these neurons are much like portraits. “Only true artists are attracted to science,” he once said. Although the majority of his work concerns the nervous sys
APA, Harvard, Vancouver, ISO, and other styles
6

Kaplan, Seth D. Fixing Fragile States. Greenwood Publishing Group, Inc., 2008. http://dx.doi.org/10.5040/9798400651755.

Full text
Abstract:
Fragile states are a menace. Their lawless environments spread instability across borders, provide havens for terrorists, threaten access to natural resources, and consign millions of people to poverty. But Western attempts to reform these benighted places have rarely made things better. Kaplan argues that to avoid revisiting the carnage and catastrophes seen in places like Iraq, Bosnia, and the Congo, the West needs to rethink its ideas on fragile states and start helping their peoples build governments and states that actually fit the local landscape. Fixing Fragile States lays bare the fata
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Cancer du sein basal-Like"

1

Cryns, Vincent L., Mervi Jumppanen, and Jorma Isola. "Basal-like Breast Cancer." In Encyclopedia of Cancer. Springer Berlin Heidelberg, 2011. http://dx.doi.org/10.1007/978-3-642-16483-5_531.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Han, Bingchen, William Audeh, Yanli Jin, Sanjay P. Bagaria, and Xiaojiang Cui. "Biology and Treatment of Basal-Like Breast Cancer." In Cell and Molecular Biology of Breast Cancer. Humana Press, 2013. http://dx.doi.org/10.1007/978-1-62703-634-4_5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Alver, Kadir Han. "Radiologic Imaging of Scalp Lesions." In The Radiology of Cancer. Nobel Tip Kitabevleri, 2024. http://dx.doi.org/10.69860/nobel.9786053359364.1.

Full text
Abstract:
Scalp lesions present significant diagnostic challenges due to their similar appearances, making accurate radiological assessment crucial in lowering mortality and morbidity rates. Understanding the scalp's anatomy, which includes five distinct layers-skin, dense connective tissue, epicranial aponeurosis, loose connective tissue, and pericranium-enables precise lesion localization. The vast majority of scalp abnormalities (93–98%) are benign, with trichilemmal cysts being the most common, followed by epidermal and dermal cysts, lipomas, nevi, and sebaceous cysts. Although less frequent
APA, Harvard, Vancouver, ISO, and other styles
4

Tranvåg, Eirik Joakim, and Roger Strand. "Rationing of Personalised Cancer Drugs: Rethinking the Co-production of Evidence and Priority Setting Practices." In Human Perspectives in Health Sciences and Technology. Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-030-92612-0_14.

Full text
Abstract:
AbstractRising health care costs is a challenge for all health care systems, and new and expensive cancer drugs is an important contributor to this. Many countries – like Norway – have therefore established priority setting institutions and systems for drug appraisals where equal treatment, neutrality and transparency are key values. Despite this, controversy surrounding drug reimbursement decisions are persistent.The development of personalised cancer medicine is seen by many as a potential solution to difficult priority setting decisions, by tailoring the right drug to the right patient at t
APA, Harvard, Vancouver, ISO, and other styles
5

Attia, Adel, Ismail Siala, and Fathi Azribi. "General Oncology Care in Libya." In Cancer in the Arab World. Springer Singapore, 2022. http://dx.doi.org/10.1007/978-981-16-7945-2_9.

Full text
Abstract:
AbstractLibya is a large country, ranking at fourth in terms of area both in the Arab world and the African continent (https://www.worldatlas.com/articles/which-are-the-10-largest-countries-of-africa-by-size.html). It is part of the World Health Organization–Eastern Mediterranean Regional Office (WHO–EMRO) region. Oil production is the main source of income which has transformed the country massively over the past 50 years and the healthcare system is one of the sectors that have improved significantly. The Health Act No (106), issued in 1973, guarantees free health services to all Libyans, wi
APA, Harvard, Vancouver, ISO, and other styles
6

Agolti, Mariela, and Lucrecia Solari. "Review of F-18 FDG PET/CT in Evaluating Response to Immunotherapy Treatment." In Beyond Becquerel and Biology to Precision Radiomolecular Oncology: Festschrift in Honor of Richard P. Baum. Springer International Publishing, 2024. http://dx.doi.org/10.1007/978-3-031-33533-4_2.

Full text
Abstract:
AbstractIntroduction: Immunotherapy is a wide-spreading therapeutic resource in oncology. The therapy is guided to improve the patient’s immune response to cancer cells, on the basis of the concept of immune surveillance by activating both cell-mediated and humoral immunity to fight cancer. Immunomodulatory monoclonal antibody therapy utilizes preformed monoclonal antibodies directed against molecular targets to regulate T-cell activation. There are three mechanisms involved in this kind of therapy: antibodies directed against the programmed death protein 1 (PD-1)/programmed death receptor lig
APA, Harvard, Vancouver, ISO, and other styles
7

Meslé, France, and Jacques Vallin. "Causes of Death at Very Old Ages, Including for Supercentenarians." In Demographic Research Monographs. Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-49970-9_7.

Full text
Abstract:
AbstractThe causes of death reported on the death certificates of the oldest old are generally seen as unreliable, and as thus providing little useful information on the process leading to death. However, in advanced countries, a majority of the people who die each year are relatively old, and the level of detail provided on medical certificates about the causes of death among this older population is improving. At the same time, scholars are becoming increasingly interested in studying not just the initial cause of death, but multiple causes of death, thereby taking all of the information rep
APA, Harvard, Vancouver, ISO, and other styles
8

Jones, Roger D., and Alan M. Jones. "A Proposed Mechanism for in vivo Programming Transmembrane Receptors." In Communications in Computer and Information Science. Springer Nature Switzerland, 2024. http://dx.doi.org/10.1007/978-3-031-57430-6_11.

Full text
Abstract:
AbstractTransmembrane G-protein coupled receptors (GPCRs) are ideal drug targets because they resemble, in function, molecular microprocessors for which outcomes (e.g. disease pathways) can be controlled by inputs (extracellular ligands). The inputs here are ligands in the extracellular fluid and possibly chemical signals from other sources in the cellular environment that modify the states of molecular switches, such as phosphorylation sites, on the intracellular domains of the receptor. Like in an engineered microprocessor, these inputs control the configuration of output switch states that
APA, Harvard, Vancouver, ISO, and other styles
9

Jain, Ankit, Vijayakumar Chellappa, and Kadambari Dharanipragada. "Inter-Relationship of Ki-67 and Triple-Negative Breast Cancer." In Breast Cancer Updates [Working Title]. IntechOpen, 2023. http://dx.doi.org/10.5772/intechopen.109586.

Full text
Abstract:
Triple-negative breast cancer (TNBC) is a heterogeneous group characterized by an early onset, aggressive course of the disease, a higher tendency of visceral metastases, and a poorer prognosis. It is also associated with basal-like phenotype and germline mutations for BRCA genes in 10–20% and somatic mutations in 3–5% of cases. Based on gene expression profiling, TNBC is divided into four tumor-specific subtypes (Basal-like 1, Basal-like 2, Mesenchymal, and Luminal androgen receptor) with different clinical, prognostic, and therapeutic implications. The Ki-67 antigen, a non-histone nuclear pr
APA, Harvard, Vancouver, ISO, and other styles
10

Zhou, Qiaochu, Yanan Zhang, Shan Zhang, Jinhui Wang, Lele Lin, and Jie Xu. "Multiple Basal Cell Carcinomas." In Skin Cancer - Past, Present and Future. IntechOpen, 2024. https://doi.org/10.5772/intechopen.111407.

Full text
Abstract:
Basal cell carcinoma is a common nonmelanoma form of skin cancer. Treating multiple basal cell carcinomas is challenging, and choosing the best treatment for multiple basal cell carcinomas is a real problem for clinicians. The treatment of multiple basal cell carcinomas has seen a progressive evolution in recent years. Several tumor suppressor genes and proto-oncogenes have been implicated in BCC pathogenesis, including the key components of the Hedgehog pathway, PTCH1 and SMO, the TP53 tumor suppressor, and members of the RAS proto-oncogene family. A variety of treatment modalities exist and
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Cancer du sein basal-Like"

1

Yoshimura, Adriana Akemi, André Mattar, Bruna S. Mota, et al. "A MULTICENTRIC STUDY ON BREAST CANCER IN ULTRA YOUNG WOMEN: II – HISTOPATHOLOGIC AND MOLECULAR DATA." In Scientifc papers of XXIII Brazilian Breast Congress - 2021. Mastology, 2021. http://dx.doi.org/10.29289/259453942021v31s1062.

Full text
Abstract:
Introduction: Ultra young women (UYW) is defined as women aged up to 30 years. UYW with BC share some unfavorable biological tumor characteristics as larger size at diagnosis, higher loca-regional recurrence rate and lower survival, and have been merited specialized care. Objectives: We aimed to determine histopathological and molecular characteristics of BC in UYW. Methods: We carried out a multicentric, observational, retrospective study of consecutive UYW patients with BC. Only patients with infiltrating BC were included. Nine Mastology Centers located in the State of São Paulo took part in
APA, Harvard, Vancouver, ISO, and other styles
2

Aly, A., Q. Yang, E. Bilal, et al. "Abnormalities of 53BP1 in Basal-Like Breast Cancer." In Abstracts: Thirty-Second Annual CTRC‐AACR San Antonio Breast Cancer Symposium‐‐ Dec 10‐13, 2009; San Antonio, TX. American Association for Cancer Research, 2009. http://dx.doi.org/10.1158/0008-5472.sabcs-09-1122.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Jonkers, J. "ES2-2: Mouse Models of Basal-Like Breast Cancer." In Abstracts: Thirty-Fourth Annual CTRC‐AACR San Antonio Breast Cancer Symposium‐‐ Dec 6‐10, 2011; San Antonio, TX. American Association for Cancer Research, 2011. http://dx.doi.org/10.1158/0008-5472.sabcs11-es2-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Quinn, Hazel M., Regina Vogel, and Walter Birchmeier. "Abstract A12: YAP and cancer stem cells in basal-like breast cancer." In Abstracts: AACR Special Conference on the Hippo Pathway: Signaling, Cancer, and Beyond; May 8-11, 2019; San Diego, CA. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/1557-3125.hippo19-a12.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Mori, H., M. Kubo, M. Yamada, et al. "Abstract P4-09-15: BRCAness and PD-L1 expression of basal-like and not basal-like triple negative breast cancer." In Abstracts: Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium; December 8-12, 2015; San Antonio, TX. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/1538-7445.sabcs15-p4-09-15.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Liu, Jin, and Philip Bernard. "Abstract 2960:TRIM29is a novel biomarker for basal-like breast cancer." In Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/1538-7445.am10-2960.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Sundaram, Sneha, David B. Darr, Kirk K. McNaughton, Joseph A. Galanko, Melissa A. Troester, and Liza Makowski. "Abstract IA45: Obesity and the microenvironment in basal-like breast cancer." In Abstracts: Seventh AACR Conference on The Science of Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; November 9-12, 2014; San Antonio, TX. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7755.disp14-ia45.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Manié, E., A. Vincent-Salomon, J. Lehmann-Che, et al. "ConsistentTP53mutations inBRCA1and sporadic basal-like breast tumors, while infrequent in luminalBRCA1tumors." In CTRC-AACR San Antonio Breast Cancer Symposium: 2008 Abstracts. American Association for Cancer Research, 2009. http://dx.doi.org/10.1158/0008-5472.sabcs-4070.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Pei, X.-H., HL Chan, S. Liu, et al. "Abstract P6-08-08: GATA3 inhibits breast basal-like tumorigenesis." In Abstracts: 2016 San Antonio Breast Cancer Symposium; December 6-10, 2016; San Antonio, Texas. American Association for Cancer Research, 2017. http://dx.doi.org/10.1158/1538-7445.sabcs16-p6-08-08.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Laine, A., S. Nagelli, E. Peuhu, et al. "PO-300 CIP2A-mediated regulation of senescence in basal-like breast cancer." In Abstracts of the 25th Biennial Congress of the European Association for Cancer Research, Amsterdam, The Netherlands, 30 June – 3 July 2018. BMJ Publishing Group Ltd, 2018. http://dx.doi.org/10.1136/esmoopen-2018-eacr25.813.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Cancer du sein basal-Like"

1

Lawson, Campbell. The Oncogenic Role of RhoGAPs in Basal-Like Breast Cancer. Defense Technical Information Center, 2015. http://dx.doi.org/10.21236/ada618217.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Fagan-Solis, Katerina. Regulation and Action of SKP2 in Cell and Tumor Models: Mechanisms Underlying Aggressive Growth in Basal-Like Breast Cancer. Defense Technical Information Center, 2011. http://dx.doi.org/10.21236/ada549245.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Fagan-Solis, Katerina. Regulation and Action of SKP2 in Cell and Tumor Models: Mechanisms Underlying Aggressive Growth in Basal-Like Breast Cancer. Defense Technical Information Center, 2011. http://dx.doi.org/10.21236/ada561142.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

MacFarlane, Andrew. 2021 medical student essay prize winner - A case of grief. Society for Academic Primary Care, 2021. http://dx.doi.org/10.37361/medstudessay.2021.1.1.

Full text
Abstract:
As a student undertaking a Longitudinal Integrated Clerkship (LIC)1 based in a GP practice in a rural community in the North of Scotland, I have been lucky to be given responsibility and my own clinic lists. Every day I conduct consultations that change my practice: the challenge of clinically applying the theory I have studied, controlling a consultation and efficiently exploring a patient's problems, empathising with and empowering them to play a part in their own care2 – and most difficult I feel – dealing with the vast amount of uncertainty that medicine, and particularly primary care, pre
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Cancer du sein basal-Like' for particular source types:
Journal articles Dissertations / Theses
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography